Long term drug efficacy testing: Introducing the 3D CoSeedis™ Tumor Relapse Assay
Long term drug efficacy, in other words tumor relapse, is an important feature in the successful treatment of cancer. Quiescent cells in tumors often resist treatment and eventually regenerate a cancerous tumor previously already thought dead. It is therefore of essence to develop treatment regiments and compounds that are capable to also eliminate dormant tumor cells effectively. However, there was no reliable ex vivo test available so far that allowed to accurately test compounds on their long term efficacy.
Relapse vs. complete tumor death: compound 1 transiently arrests tumor growth (red arrows) before relapse occurs. In comparison, compound 2 fully eliminates tumor growth (blue line).
With the 3D CoSeedis™ Drug Efficacy Assay, this deficit has been eliminated. The assay is capable to effectively detect and monitor tumor relapse with a high sensitivity and constitutes the first assay of this class on the market.
The 3D CoSeedis™ Drug Efficacy Assay offers the following unique features:
Measures tumor growth of 400 micro-tumors per data point to accurately detect changes in growth rate
Allows cultivation of micro-tumors of up to 11 weeks to pick up late relapse events
Allows multi-plexing with the 3D CoSeedis™ Cytotoxicity in chip Assay, the 3D CoSeedis™ Apoptosis in chip Assay, the 3D CoSeedis™ Histology Assay and the 3D CoSeedis™ Dose Response Assay to provide reliable and accurate high-content data.
The 3D CoSeedis™ Drug Efficacy Assay is part of abc biopply’s comprehensive service package to test compounds on reliable and accurate preclinical disease models.